Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

VAR-505

10 evidence topics · 1 source

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“VAR-505”
Sponsor“Immunome, Inc.”
Overall status“Recruiting”
Study start (actual)“2026-05-21”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-05”
First posted“2026-05-27”
Last update posted“2026-10-29”
Site“Celerion, Inc.”; “Tempe”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment
Study characteristicQuoted record
Enrollment (estimated)“44”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
  • The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
  • The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.